Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Shire Share Price (SHP)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 3,202.00on 18-02-2018at 16:30:00
Change 0.00 0.69%
Buy 3,210.50
Sell 3,208.50
Buy / Sell SHP Shares
Last Trade: Sell 15,348 at 3,202.00p
Day's Volume: 3,248,059
Last Close: 3,202.00p
Open: 3,206.50p
Day's Range 3,179.50p - 3,237.00p
52wk Range: 3,034.00p - 5,067.00p
Market Capitalisation: £29,131m
VWAP: 0.00p
Shares in Issue: 910m

Recent Trades History Shire (SHP)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell*15,3483,202.0018:08:54 - 16-Feb-18
Buy*1163,226.14518:38:27 - 16-Feb-18
Buy*43,219.66618:38:24 - 16-Feb-18
Sell*50,0423,203.3118:38:17 - 16-Feb-18
Buy*7,3653,213.59718:12:22 - 16-Feb-18
Buy*23,6893,213.89618:10:47 - 16-Feb-18
Buy*24,2263,215.59718:05:31 - 16-Feb-18
Delayed publication
17:51:26 - 16-Feb-18
Delayed publication
17:45:07 - 16-Feb-18
Delayed publication
17:16:54 - 16-Feb-18

Share Price History for Shire

Time period:
Date Open High Low Close Volume
16th Feb 2018 (Fri)3,206.503,237.003,179.503,202.003,358,197
15th Feb 2018 (Thu)3,160.003,209.503,136.503,180.004,001,734
14th Feb 2018 (Wed)3,198.003,325.003,065.503,135.507,497,179
13th Feb 2018 (Tue)3,180.003,202.503,149.003,181.003,535,691
12th Feb 2018 (Mon)3,098.503,197.003,080.003,197.004,121,431
9th Feb 2018 (Fri)3,062.003,096.003,034.003,075.005,212,325
8th Feb 2018 (Thu)3,146.003,188.503,090.003,093.502,681,975
7th Feb 2018 (Wed)3,170.003,187.003,119.003,167.502,811,375
6th Feb 2018 (Tue)3,100.003,223.503,081.003,137.503,662,079
5th Feb 2018 (Mon)3,280.003,280.503,205.503,216.503,500,125
2nd Feb 2018 (Fri)3,317.003,338.003,273.003,313.502,819,510
1st Feb 2018 (Thu)3,284.003,330.503,254.003,320.003,526,138
31st Jan 2018 (Wed)3,415.003,423.003,316.003,327.503,640,176
30th Jan 2018 (Tue)3,462.503,494.503,393.003,426.502,230,671
29th Jan 2018 (Mon)3,460.003,497.503,432.003,474.503,135,548
26th Jan 2018 (Fri)3,388.503,453.503,375.253,439.004,545,217
25th Jan 2018 (Thu)3,405.003,480.003,341.503,364.005,339,451
24th Jan 2018 (Wed)3,511.503,522.003,430.503,424.002,751,448
23rd Jan 2018 (Tue)3,529.503,551.503,498.003,510.003,148,193
22nd Jan 2018 (Mon)3,494.003,578.003,470.003,511.004,091,433
19th Jan 2018 (Fri)3,489.503,589.003,347.253,461.004,325,434

SHP - Shire Investor Summary

Shire plc, formerly known as Shire Ltd, is a specialist pharmaceutical company that has a vested interest in the areas of Attention Deficit Hyperactivity Disorder, novel genetic therapies and gastrointestinal diseases. Founded in 1986, the company primarily concentrated on the prevention and treatment of osteoporosis before branching out into other neglected medical areas. Today Shire is considered to have global significance with regards to the pharmaceutical industry and its main products now target the US, Canada, the UK and Europe. Shire also has distributors throughout the rest of the world. The company already has a range of highly effective drug products on the market and are committed to further improvement of novel therapeutics which are already in the late stages of their development.

The company's main areas of expertise lie in product development and risk management and by successfully merging with 7 large companies over the last ten years, Shire has become one of the fastest growing pharmaceutical companies to date. In 1997 they acquired both Pharmavene Inc and Richwood Pharmaceutical Company Inc. Then in 1999 Shire Ltd merged with the global leader Fuisz Technologies and Roberts Pharmaceutical Corporation. Today, their share price reflects their successful growth. Shire Ltd has its global headquarters in the UK with an additional headquarters in the US – the two countries that make most use of the companies approved products. Other offices have been opened around the world over the last few years so that the majority of the products Shire Ltd promotes are now available in over 40 countries.

News about Shire (SHP)

FTSE Slips as Shire Struggles

News - Tuesday, August 22, 2017

The FTSE 100 endured a difficult trading day as house prices slid by 0.9 percent, and the pharmaceuticals giant Shire was hit hard by the surprising departure of Jeff Poulton, its chief financial officer. Poulton had helped to lead the company through the acquisition of Dyax, amd through its mega-merger with the pharmaceuticals company Baxalta, and he will remain in his position for the third quarter reporting period....

Liberum Identifies Potentially Underperforming FTSE 100 Companies

News - Wednesday, July 19, 2017

Analysts at Liberum have identified a list of companies that they believe may be at risk of underperforming. The broker has studied the FTSE 100 companies, to identify the ones that it refers to as ‘sinners’....

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered